Lipid Peroxidation Biochemistry and Pathology
Lipid peroxidation is a chain reaction: initiation (ROS abstracts H from polyunsaturated fatty acid, generating carbon-centred radical); propagation (O2 addition forms peroxyl radical ROO⋅, which abstracts H from adjacent PUFA continuing chain reaction); and termination (two radicals combine, or chain-breaking antioxidant donates H). Products include: lipid hydroperoxides (LOOH; immediate toxic products); 4-hydroxynonenal (4-HNE; Michael acceptor forming protein/DNA adducts at Cys/His/Lys residues); malondialdehyde (MDA; crosslinks proteins and DNA); isoprostanes (F2-isoprostanes; gold standard in vivo lipid peroxidation biomarker); and oxidised phospholipids (OxPL; TLR4 activators, PAF receptor ligands). Cell membranes (30–40% PUFA in phospholipid headgroups — arachidonyl, DHA, EPA) are primary targets; mitochondrial cardiolipin (18:2 linoleic-rich) peroxidation disrupts OXPHOS supercomplex structure.
Spirulina Anti-Peroxidation Mechanisms
Carotenoid Chain-Breaking Radical Quenching
Spirulina carotenoids (β-carotene, zeaxanthin, cryptoxanthin; ~170 mg β-carotene/100g) partition into membrane lipid bilayers due to their hydrophobic polyene chains, positioning themselves at the membrane interface where lipid radical chain reactions initiate. β-Carotene reacts with peroxyl radicals (ROO⋅) at rate k = 107–108 M−1;s−1;, terminating chain reactions and preventing further PUFA oxidation propagation. Zeaxanthin’s hydroxyl groups improve membrane partitioning in phospholipid bilayers (vs. β-carotene’s pure hydrocarbon), providing superior chain-breaking activity in polar membrane environments. In erythrocyte membrane lipid peroxidation assays, spirulina supplementation reduces membrane MDA by 25–40%.
Nrf2–GPx4 Upregulation and Phospholipid Hydroperoxide Reduction
GPx4 (glutathione peroxidase 4; phospholipid hydroperoxide GPx) is uniquely capable of reducing phospholipid hydroperoxides (PLOOH) while they remain esterified in membranes — other GPx isoforms require phospholipase A2 liberation first. GPx4 uses GSH as electron donor (GSH + PLOOH → GSSG + PLOH). GPx4 loss causes ferroptosis (iron-dependent regulated cell death via uncontrolled PLOOH accumulation). Spirulina Nrf2 activation upregulates GPx4 expression +20–30% (Nrf2 ARE in GPx4 promoter), providing enhanced in-membrane PLOOH reduction. Combined with GSH maintenance (+20–35% GSH provision), GPx4 activity is both kinetically and substrate-optimally supported, reducing plasma phospholipid hydroperoxides by 25–40%.
4-HNE Protein Adduct Prevention and Detoxification
4-Hydroxynonenal (4-HNE) is the most reactive lipid peroxidation secondary product: it forms Michael addition adducts with Cys, His, and Lys residues in proteins, impairing enzyme function. 4-HNE adducts accumulate in: AD brains (synaptosomes — impairing glucose transport, neurotransmitter release); atherosclerotic plaques (modified apoB, creating OxLDL); diabetic tissue (impairing insulin signalling components IRS-1, PI3K); and ageing muscle (impairing proteasomal degradation of damaged proteins). Spirulina reduces plasma and tissue 4-HNE protein adducts by 20–35% (combined carotenoid radical termination preventing 4-HNE formation + Nrf2-driven ALDH3A1 upregulation +15–25% for 4-HNE oxidation to non-toxic 4-hydroxynonenoic acid).
Ferroptosis Protection and CoQ10 Role
Ferroptosis (iron-dependent cell death driven by PLOOH accumulation when GPx4 is inhibited or GSH depleted) is implicated in neurodegeneration, ischaemia-reperfusion injury, and cancer therapy resistance. Spirulina’s multi-pronged anti-ferroptosis activity: GPx4 upregulation (+20–30%), GSH maintenance (+20–35%), phycocyanin iron chelation (reducing free Fe2+ driving Fenton-generated initiating radicals), and Nrf2→ferritin upregulation (sequestering reactive labile iron pool). Coenzyme Q10 (present in mitochondria and membranes; chain-breaking antioxidant; DHODH enzyme in GPx4-independent ferroptosis suppression) is produced via the mevalonate pathway that spirulina AMPK/Nrf2 pathway supports (+10–15% CoQ10 in ageing models).
Clinical Outcomes in Lipid Peroxidation
- Plasma MDA: −25–40% at 8–12 weeks
- F2-isoprostanes (8-iso-PGF2α; gold standard): −20–35%
- 4-HNE protein adducts (plasma): −20–35%
- OxLDL: −15–25%
- Erythrocyte membrane MDA: −25–40%
- Plasma phospholipid hydroperoxides (PLOOH): −25–40%
Dosing and Drug Interactions
Lipid peroxidation/membrane protection: 5–10g daily; fat-soluble carotenoids better absorbed with dietary fat. Vitamin E (tocopherol): Synergistic chain-breaking antioxidant; vitamin E regeneration by spirulina polyphenols/ascorbate extends tocopherol efficacy. Statins: Statins reduce CoQ10 production (mevalonate inhibition); spirulina partial CoQ10 support is complementary. Chemotherapy oxidative stress: Timing caution — some chemotherapy mechanisms involve ROS; discuss antioxidant timing with oncologist. Summary: MDA −25–40%, GPx4 +20–30%, GSH +20–35%, 4-HNE −20–35%, ferroptosis protection; dosing 5–10g daily with fat. NK concern: low.